Medical Oncology

Uzm. Dr. Burcu Caner

Doctor and researcher Aydın Şehir Hastanesi Aydın
Breast NeoplasmsLung NeoplasmsCarcinoma, HepatocellularLiver Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 4 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Lung Neoplasms 2 publications
  • Carcinoma, Hepatocellular 2 publications
  • Liver Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionAydın Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 4 publications · Model version —From source
  • Publications56 publicationsORCID, OpenAlexFrom source
  • ORCID0000-0003-1591-3323ORCIDFrom source
  • Last synchronised5 November 2026 07:34https://aydinsehir.saglik.gov.tr/TR-1554205/doktorlarimiz.html#burcu-canersaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

56 publications

  1. Predictors of hepatotoxicity in patients receiving CDK4/6 inhibitors: A real-world cohort study

    Journal of Oncology Pharmacy Practice, 2026

    DOI 10.1177/10781552261447894 PMID 42132917 Source: ORCID

  2. Long-Term Survival of Cancer Patients Following COVID-19 Infection: Prognostic Value of Inflammatory Indices and Vaccination Status

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2026

    DOI 10.32708/uutfd.1898579 Open-access full textSource: ORCID

  3. Predicting the Unpredictable: Prognostic Role of Systemic Inflammatory Indices and Tumor Biology of Neoadjuvant Chemotherapy Response in Gastric and Gastroesophageal Junction Cancer—Insights from a Systematic Review and Real-World Experience

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041484 PMID 41753172 Open-access full textSource: ORCID

  4. Survival Outcomes in Metaplastic Versus Triple-Negative Invasive Breast Carcinoma: A Propensity Score-Matched Study

    Medicina, 2026

    DOI 10.3390/medicina62101944 PMID 42942475 Open-access full textSource: ORCID

  5. Prognostic Value of Immunonutritional Status and Radiologic Muscle Mass in Older Patients Receiving Immune Checkpoint Inhibitors: A Real-World Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33080480 PMID 42645385 Open-access full textSource: ORCID

  6. Psychological impact of CDK4/6 inhibitors in HR+/HER2-advanced breast cancer: Insomnia, anxiety and menopausal symptoms assessed by the Nottingham health profile

    Irish journal of medical science, 2026

    DOI 10.1007/s11845-025-04255-1 PMID 41483094 Source: ORCID

  7. Optimizing Patient Selection for Bevacizumab Plus Irinotecan in Recurrent High Grade Glioma: Superiority of the Neutrophil-to-Lymphocyte Ratio Over Other Systemic Inflammation Indices

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.263037 Source: OpenAlex

  8. Predictive value of morphological, functional, and nutritional markers in elderly patients with advanced squamous cell lung cancer receiving gemcitabine plus carboplatin: A multidimensional "triple-risk" approach

    The Atlantic Journal of Medical Science and Research, 2026

    DOI 10.5455/atjmed.2026.01.012 Open-access full textSource: OpenAlex

  9. Metastatik Meme Kanserinde Parenteral ve Oral Tedavilerin Psikolojik ve Yaşam Kalitesi Üzerindeki Etkileri: Karşılaştırmalı Analiz

    Journal of Anatolian Medical Research, 2025

    DOI 10.55694/jamer.1815786 Open-access full textSource: ORCID

  10. Primary neuroendocrine tumors of the breast according to the WHO 2019 classification; real life experiences of rare tumor types of the breast

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf171 PMID 40588422 Open-access full textSource: ORCID

View all 56 publications